What is the optimum thiamine dose to treat or prevent Wernicke's encephalopathy or Wernicke-Korsakoff syndrome? Results of a randomized controlled trial.

Alcohol Clin Exp Res · 2022 · PMC9321884 · PMID 35428992

Europe PMC DOI

hedged sentences

0.0610

closest p · 1.2× alpha

0.0650

boldest claim

The sentences

approached but did not reach significancep = 0.061so close (0.05 < p ≤ 0.1)

“low dose” (i.e., <200 mg twice daily) IV thiamine regimens in patients with Wernicke's encephalopathy failed to detect a significant difference in clinical characteristics between the two dosage groups (although an association between higher dose and lower mortality approached but did not reach significance p = 0.061 after controlling for potential confounders) (Nakamura et al., 2018 ).

also in 210 other papers

marginally nonsignificantp = 0.065so close (0.05 < p ≤ 0.1)

Asymptomatic At‐Risk patients showed significant improvements on the RUDAS and Story Recall at all dosage levels (except 100 mg TDS was marginally nonsignificant on story recall p = 0.065).

also in 448 other papers

marginally significantno p-value reported

There was a marginally significant difference in story memory recall between the 300 mg TDS and the 100 mg TDS conditions for the Asymptomatic At‐risk group only.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.